NEW YORK (GenomeWeb) – Genomenon and GenomOncology announced today that they have formed a partnership to incorporate Genomenon's Mastermind search engine into GenomOncology's Molecular Tumor Board software, in order to help oncologists make more informed clinical decisions.
Cleveland-based GenomOncology will use the Mastermind search capability to deliver the most current genomic research to oncologists as they review next-generation sequencing panels. This will help clinicians easily determine if there is any relevant literature related to each patient's specific mutation, the firm said. The latest version of Mastermind, released in September, indexes approximately 500,000 new genomic variants from supplemental data found in scientific publications.
"Precision medicine is about putting the best tools, information, and knowledge about the patient's tumor into the hands of the experts to provide the best medical treatment for cancer patients," Genomenon CEO Mike Klein said in a statement.
"We know oncologists need to make timely decisions for patients, but are extremely pressed for time and overwhelmed with the amount of information out there. Providing them tools to make that easier is critical, especially as the field of oncology continues to change rapidly," added GenomOncology Founder and CEO Manuel Glynias. "Integrating Genomenon's Mastermind is one of the ways we are doing this.".
Less than two weeks ago, Ann Arbor, Michigan-based Genomenon signed a deal with Fabric Genomics to integrate their respective genomic interpretation technologies and co-market the combined offering.
The vendor has also received a two-year, $1.5 million Small Business Innovation Research grant from the National Institutes of Health to add artificial intelligence to variant interpretation. Genomenon is automating the curation of literature though a technique it calls genomic language processing.